# CVB Financial Corp: financial statements, quarterly

CVBF · Nasdaq · CIK 354647 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cvbf.md) · [Financials](/companies/cvbf/financials.md) · [Filings](/companies/cvbf/filings.md) · [Insiders](/companies/cvbf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cvbf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [32.9](/filings/0000950170-23-061771.md) | [38.7 d](/filings/0000950170-24-022216.md) | [45.2](/filings/0000950170-24-056453.md) | [48.2](/filings/0000950170-24-093517.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [22.7](/filings/0000950170-24-123143.md) | [26.1 d](/filings/0001193125-26-083221.md) | [18.2](/filings/0000950170-25-067879.md) | [18.7](/filings/0000950170-25-105728.md) | [16.4](/filings/0001193125-25-272614.md) | [17.2 d](/filings/0001193125-26-083221.md) | [18.4](/filings/0001193125-26-214674.md) | [18.2](/filings/0001193125-26-340248.md) | [16.4](/filings/0001193125-25-272614.md) | [19.3 d](/filings/0001193125-26-083221.md) | [17.5](/filings/0001193125-26-214674.md) | [16.8](/filings/0001193125-26-340248.md) |
| Net income | $m | [57.9](/filings/0000950170-24-123143.md) | [48.5 d](/filings/0001193125-26-083221.md) | [48.6](/filings/0000950170-25-067879.md) | [50.0](/filings/0000950170-25-105728.md) | [51.2](/filings/0001193125-25-272614.md) | [50.9 d](/filings/0001193125-26-083221.md) | [51.1](/filings/0001193125-26-214674.md) | [50.6](/filings/0001193125-26-340248.md) | [52.6](/filings/0001193125-25-272614.md) | [55.0 d](/filings/0001193125-26-083221.md) | [51.0](/filings/0001193125-26-214674.md) | [48.3](/filings/0001193125-26-340248.md) |
| Diluted EPS | $ per share | [0.42](/filings/0000950170-24-123143.md) | not reported | [0.35](/filings/0000950170-25-067879.md) | [0.36](/filings/0000950170-25-105728.md) | [0.37](/filings/0001193125-25-272614.md) | not reported | [0.36](/filings/0001193125-26-214674.md) | [0.37](/filings/0001193125-26-340248.md) | [0.38](/filings/0001193125-25-272614.md) | not reported | [0.38](/filings/0001193125-26-214674.md) | [0.29](/filings/0001193125-26-340248.md) |
| Basic EPS | $ per share | [0.42](/filings/0000950170-24-123143.md) | not reported | [0.35](/filings/0000950170-25-067879.md) | [0.36](/filings/0000950170-25-105728.md) | [0.37](/filings/0001193125-25-272614.md) | not reported | [0.37](/filings/0001193125-26-214674.md) | [0.37](/filings/0001193125-26-340248.md) | [0.38](/filings/0001193125-25-272614.md) | not reported | [0.38](/filings/0001193125-26-214674.md) | [0.29](/filings/0001193125-26-340248.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.2](/filings/0000950170-23-061771.md) | [0.3](/filings/0000950170-25-029985.md) | [0.9](/filings/0000950170-24-056453.md) | [0.8](/filings/0000950170-24-093517.md) | [0.5](/filings/0000950170-24-123143.md) | [0.2](/filings/0001193125-26-083221.md) | [0.5](/filings/0000950170-25-067879.md) | [0.7](/filings/0000950170-25-105728.md) | [0.8](/filings/0001193125-25-272614.md) | [0.4](/filings/0001193125-26-340248.md) | [0.5](/filings/0001193125-26-214674.md) | [1.1](/filings/0001193125-26-340248.md) |
| Total assets | $bn | [15.9](/filings/0000950170-23-061771.md) | [16.0](/filings/0000950170-25-029985.md) | [16.5](/filings/0000950170-24-056453.md) | [16.2](/filings/0000950170-24-093517.md) | [15.4](/filings/0000950170-24-123143.md) | [15.2](/filings/0001193125-26-083221.md) | [15.3](/filings/0000950170-25-067879.md) | [15.4](/filings/0000950170-25-105728.md) | [15.7](/filings/0001193125-25-272614.md) | [15.6](/filings/0001193125-26-340248.md) | [15.5](/filings/0001193125-26-214674.md) | [21.2](/filings/0001193125-26-340248.md) |
| Total liabilities | $bn | [14.0](/filings/0000950170-23-061771.md) | [13.9](/filings/0000950170-25-029985.md) | [14.4](/filings/0000950170-24-056453.md) | [14.0](/filings/0000950170-24-093517.md) | [13.2](/filings/0000950170-24-123143.md) | [13.0](/filings/0001193125-26-083221.md) | [13.0](/filings/0000950170-25-067879.md) | [13.2](/filings/0000950170-25-105728.md) | [13.4](/filings/0001193125-25-272614.md) | [13.3](/filings/0001193125-26-340248.md) | [13.2](/filings/0001193125-26-214674.md) | [18.0](/filings/0001193125-26-340248.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $bn | not reported | [1.0](/filings/0000950170-24-022216.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [2.0](/filings/0000950170-24-123143.md) | [2.1](/filings/0001193125-26-083221.md) | [2.1](/filings/0000950170-25-105728.md) | [2.1](/filings/0001193125-25-272614.md) | [2.2](/filings/0001193125-25-272614.md) | [2.2](/filings/0001193125-26-340248.md) | [2.2](/filings/0001193125-26-340248.md) | [2.2](/filings/0001193125-26-340248.md) | [2.3](/filings/0001193125-25-272614.md) | [2.3](/filings/0001193125-26-340248.md) | [2.3](/filings/0001193125-26-340248.md) | [3.2](/filings/0001193125-26-340248.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [84.8 d](/filings/0000950170-24-123143.md) | [48.7 d](/filings/0001193125-26-083221.md) | [77.5](/filings/0000950170-25-067879.md) | [26.1 d](/filings/0000950170-25-105728.md) | [71.4 d](/filings/0001193125-25-272614.md) | [74.8 d](/filings/0001193125-26-083221.md) | [41.9](/filings/0001193125-26-214674.md) | [53.1 d](/filings/0001193125-26-340248.md) | [81.5 d](/filings/0001193125-25-272614.md) | [44.9 d](/filings/0001193125-26-083221.md) | [62.4](/filings/0001193125-26-214674.md) | [388 d](/filings/0001193125-26-340248.md) |
| Capital expenditure | $m | [0.5 d](/filings/0000950170-24-123143.md) | [1.6 d](/filings/0001193125-26-083221.md) | [0.2](/filings/0000950170-25-067879.md) | [1.8 d](/filings/0000950170-25-105728.md) | [1.2 d](/filings/0001193125-25-272614.md) | [2.0 d](/filings/0001193125-26-083221.md) | [0.7](/filings/0001193125-26-214674.md) | [0.9 d](/filings/0001193125-26-340248.md) | [0.8 d](/filings/0001193125-25-272614.md) | [1.7 d](/filings/0001193125-26-083221.md) | [1.1](/filings/0001193125-26-214674.md) | [0.8 d](/filings/0001193125-26-340248.md) |
| Dividends paid | $m | [27.9 d](/filings/0000950170-24-123143.md) | [27.9 d](/filings/0001193125-26-083221.md) | [28.0](/filings/0000950170-25-067879.md) | [27.9 d](/filings/0000950170-25-105728.md) | [27.9 d](/filings/0001193125-25-272614.md) | [27.9 d](/filings/0001193125-26-083221.md) | [27.9](/filings/0001193125-26-214674.md) | [28.0 d](/filings/0001193125-26-340248.md) | [27.6 d](/filings/0001193125-25-272614.md) | [27.5 d](/filings/0001193125-26-083221.md) | [27.1](/filings/0001193125-26-214674.md) | [27.3 d](/filings/0001193125-26-340248.md) |
| Share repurchases | $m | [0.1 d](/filings/0000950170-24-123143.md) | [0.0 d](/filings/0001193125-26-083221.md) | [2.6](/filings/0000950170-25-067879.md) | [0.0 d](/filings/0000950170-25-105728.md) | [0.0 d](/filings/0001193125-25-272614.md) | [0.2 d](/filings/0001193125-26-083221.md) | [18.7](/filings/0001193125-26-214674.md) | [22.5 d](/filings/0001193125-26-340248.md) | [6.1 d](/filings/0001193125-25-272614.md) | [33.8 d](/filings/0001193125-26-083221.md) | [3.1](/filings/0001193125-26-214674.md) | [2.1 d](/filings/0001193125-26-340248.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [139](/filings/0000950170-23-061771.md) | [139](/filings/0000950170-24-056453.md) | [138](/filings/0000950170-24-093517.md) | [138](/filings/0000950170-24-123143.md) | [139](/filings/0000950170-25-067879.md) | [139](/filings/0000950170-25-105728.md) | [139](/filings/0001193125-25-272614.md) | [139](/filings/0001193125-26-214674.md) | [137](/filings/0001193125-26-340248.md) | [137](/filings/0001193125-25-272614.md) | [135](/filings/0001193125-26-214674.md) | [167](/filings/0001193125-26-340248.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 175,997,435 at 2026-08-03, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340248.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.